Researchers at the Baltimore-based biotech company Delfi Diagnostics have developed a machine learning-based blood testing technology that could greatly help detect early stages of lung cancer.
The researchers are hoping that improved screening and detection technologies could allow more cases of lung cancer to be spotted earlier, which could greatly improve outcomes.
“These results suggest that the Delfi lung cancer screening technology could help reduce lung cancer deaths by offering a convenient, high-performing test to people who are [United States Preventive Services Taskforce] eligible,” Delfi CMO Peter Bach said in a statement.
“We have already begun enrollment of a 1,700-patient, prospective, case-control study to generate the clinical evidence that would underpin a commercial lung screening test,” he added.
Comments are closed.